Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
Yale University School of Medicine
mi
from
New Haven, CT
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
Infinity Clinical Research, LLC
mi
from
Hollywood, FL
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
Infinity Clinical Research, LLC
mi
from
Hollywood, FL
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
QUEST Research Institute
mi
from
Farmington Hills, MI
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
QUEST Research Institute
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
Spectrum Health
mi
from
Grand Rapids, MI
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
Washington University
mi
from
St. Louis, MO
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
Winthrop University Hospital Clinical Trials Center
mi
from
Mineola, NY
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
Winthrop University Hospital Clinical Trials Center
mi
from
Mineola, NY
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
Temple University Hospital
mi
from
Philadelphia, PA
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
MUSC (Medical University of South Carolina)
mi
from
Charleston, SC
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
MUSC (Medical University of South Carolina)
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
UVM MRI Center for Biomedical Imaging
mi
from
Burlington, VT
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
UVM MRI Center for Biomedical Imaging
mi
from
Burlington, VT
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
University of Washington Medical Center
mi
from
Seattle, WA
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
Fundacion Abood Shaio
mi
from
Bogota,
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
Fundacion Abood Shaio
mi
from
Bogota,
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Cancer Research Center of Hawaii
mi
from
Honolulu, HI
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Cancer Research Center of Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Maine Children's Cancer Program
mi
from
Scarborough, ME
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Maine Children's Cancer Program
mi
from
Scarborough, ME
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Spectrum Health and DeVos Children's Hospital
mi
from
Grand Rapids, MI
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Spectrum Health and DeVos Children's Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Children's Hospital of Omaha
mi
from
Omaha, NE
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Children's Hospital of Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Albert Einstein Clinical Cancer Center
mi
from
Bronx, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Albert Einstein Clinical Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Winthrop University Hospital
mi
from
Mineola, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
NYU School of Medicine's Kaplan Comprehensive Cancer Center
mi
from
New York, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
NYU School of Medicine's Kaplan Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Beth Israel Hospital North
mi
from
New York, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Beth Israel Hospital North
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
State University of New York Health Sciences Center - Stony Brook
mi
from
Stony Brook, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
State University of New York Health Sciences Center - Stony Brook
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Children's Hospital
mi
from
Buenos Aires,
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Children's Hospital
mi
from
Buenos Aires,
Click here to add this to my saved trials
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases
Status: Enrolling
Updated:  12/2/2015
Emory University Hospital
mi
from
Atlanta, GA
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases
Status: Enrolling
Updated: 12/2/2015
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases
Status: Enrolling
Updated:  12/2/2015
The Emory Clinic
mi
from
Atlanta, GA
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases
Status: Enrolling
Updated: 12/2/2015
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Barrow Neurological Institute
mi
from
Phoenix, AZ
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Denise Damek
mi
from
Aurora, CO
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Denise Damek
mi
from
Aurora, CO
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Northwestern University
mi
from
Chicago, IL
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Indiana University Medical Center
mi
from
Indianapolis, IN
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Massachusetts General Hospital
mi
from
Boston, MA
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
University of Massachusetts
mi
from
Worcester, MA
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
University of Massachusetts
mi
from
Worcester, MA
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Henry Ford Health System
mi
from
Detroit, MI
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Washington University
mi
from
St. Louis, MO
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Good Samaritan Hospital/Tri Health Hatton Center
mi
from
Cincinnati, OH
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Good Samaritan Hospital/Tri Health Hatton Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
Baylor University Medical Center - Dallas
mi
from
Dallas, TX
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
Baylor University Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
University of Vermont/Fletcher Allen Healthcare
mi
from
Burlington, VT
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
University of Vermont/Fletcher Allen Healthcare
mi
from
Burlington, VT
Click here to add this to my saved trials
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated:  12/2/2015
University of Virginia Health System
mi
from
Charlottesville, VA
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Status: Enrolling
Updated: 12/2/2015
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas
A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With Recurrent WHO Grade II Gliomas
Status: Enrolling
Updated:  12/4/2015
UPMC Hillman Cancer Center (University of Pittsburgh Cancer Institute)
mi
from
Pittsburgh, PA
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas
A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With Recurrent WHO Grade II Gliomas
Status: Enrolling
Updated: 12/4/2015
UPMC Hillman Cancer Center (University of Pittsburgh Cancer Institute)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials